Open AccessMonitoring Serum VEGF in Neoadjuvant Chemotherapy for Patients with Triple‐Negative Breast Cancer: A New Strategy for Early Prediction of Treatment Response and Patient Survival
Author(s) -
Wang RuoXi,
Chen Sheng,
Huang Liang,
Zhou Ying,
Shao ZhiMing
Publication year - 2019
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2017-0602
Subject(s) - medicine , oncology , breast cancer , chemotherapy , triple negative breast cancer , vegf receptors , neoadjuvant therapy , triple negative , cancer
Background This study aimed to investigate the clinical utility of serum biomarker changes during neoadjuvant chemotherapy (NAC) for triple‐negative breast cancer (TNBC). Methods A total of 303 patients with TNBC were included in this study. Serum samples were taken at three time points during NAC: baseline, prior to the third cycle, and prior to surgery. Luminex multibiomarker panel for 29 serum biomarkers was used to detect their correlation with NAC response. The predictive and prognostic value of each selected biomarker was then studied. Results Vascular endothelial growth factor (VEGF) was the only biomarker that correlated with treatment response, with a decreasing trend in pCR patients relative to non‐pCR patients ( p < .001). Univariable and multivariable analyses revealed that the relative change in VEGF prior to the third cycle of NAC had a remarkable predictive value for both pCR and pathological nonresponse with high sensitivity and specificity. VEGF was also independently correlated with disease‐free survival. Conclusion Our findings indicate that monitoring serum VEGF could help identify patients with different responses at an early time point of NAC and at varying risk of disease relapse. Serum VEGF may also serve as an alternative to traditional response‐evaluating methodologies in tailoring and modifying the NAC strategy for both operable and advanced TNBCs. Implications for Practice Neoadjuvant chemotherapy (NAC) followed by definitive surgery is a standard of care for locally advanced breast cancer. The identification of sensitive responders to neoadjuvant therapy is highly significant for breast cancer, especially triple‐negative breast cancer (TNBC). Results of this study indicate that the monitoring of serum vascular endothelial growth factor (VEGF) could identify patients with favorable or poor responses at an early time point of NAC. Furthermore, the prediction power of VEGF was better than traditional response‐evaluating methods. VEGF might serve as a complement or alternative to traditional imaging‐based response‐evaluating methodologies in tailoring systemic treatment strategies for both operable and advanced TNBCs.